Genentech sees advantages in size, Avastin trial halted

03/24/2007 | San Diego Union-Tribune · CNNMoney

A trial of Genentech's Avastin for treating small-cell lung cancer in combination with radiation and chemotherapy was halted when some patients developed holes between their trachea and esophagus. Genentech's CEO, in presenting the company's outlook, said the firm has "a lot of advantages" because of its growing size and aims to bring 30 experimental drugs into clinical development by 2010.

View Full Article in:

San Diego Union-Tribune · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC